Richard L. Schilsky, MD, on Highlights of the 2016 ASCO Annual Meeting

2016 ASCO Annual Meeting

Richard L. Schilsky, MD, ASCO’s Chief Medical Officer, discusses the key presentations at this year’s conference.

Fabrice Denis, MD, PhD, on Lung Cancer: Improving OS With an App (French Language Version)

Fabrice Denis, MD, PhD, of the Institut Inter-regional de Cancérologie Jean Bernard, discusses findings from a phase III trial on an app used between visits for early detection of symptomatic relapse and complications in high-risk lung cancer patients (Abstract LBA9006).

To see the English language version of this discussion, click here.

Leukemia

Lymphoma

Sagar Lonial, MD, and Andrew Zelenetz, MD, PhD, on MCL, DLBCL, CLL: How Much Rituximab Is Enough?

Sagar Lonial, MD, of Emory University School of Medicine, and Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, discuss newly reported findings on rituximab maintenance therapy in hematologic malignancies (Abstracts 7503, 7504, and 7505).

Breast Cancer

Hope S. Rugo, MD, on HER2+ Breast Cancer: Findings on a Trastuzumab Biosimilar

Hope S. Rugo, MD, of the University of California, San Francisco, discusses phase III study results on a new possible alternative to trastuzumab for HER2-positive metastatic breast cancer: the biosimilar known as Myl-1401O (Abstract LBA503).

Global Cancer Care

Lawrence N. Shulman, MD, and Daniel A. Goldstein, MD: Expert Perspectives on Issues in Global Cancer Care

Lawrence N. Shulman, MD, of Abramson Cancer Center at the University of Pennsylvania, and Daniel A. Goldstein, MD, of the Rabin Medical Center, discuss global challenges in cancer care, including treating patients in areas lacking resources, and cancer drug price disparities (Abstract LBA6500).

Skin Cancer

Anthony J. Olszanski, RPh, MD, and Caroline Robert, MD, PhD, on Results From the KEYNOTE-001 Melanoma Trial

Anthony J. Olszanski, RPh, MD, of Fox Chase Cancer Center, and Caroline Robert, MD, PhD, of Gustave Roussy and Paris-Sud University, discuss study findings on pembrolizumab and the overall survival benefit for patients with advanced disease (Abstract 9503).

Oct

Today In Oncology

Richard L. Schilsky, MD, on Highlights of the 2016 ASCO Annual Meeting

Related Videos

Fabrice Denis, MD, PhD, on Lung Cancer: Improving OS With an App (French Language Version)

Sagar Lonial, MD, and Andrew Zelenetz, MD, PhD, on MCL, DLBCL, CLL: How Much Rituximab Is Enough?

Hope S. Rugo, MD, on HER2+ Breast Cancer: Findings on a Trastuzumab Biosimilar

Lawrence N. Shulman, MD, and Daniel A. Goldstein, MD: Expert Perspectives on Issues in Global Cancer Care

Anthony J. Olszanski, RPh, MD, and Caroline Robert, MD, PhD, on Results From the KEYNOTE-001 Melanoma Trial

FDA Approves Combination Regimen for Extensive-Stage SCLC

Amivantamab Plus Lazertinib vs Osimertinib in EGFR-Mutated Advanced NSCLC

In Extensive-Stage Small Cell Lung Cancer Novel Maintenance Regimen Boosts Overall Survival

Fertility-Sparing Surgery vs Hysterectomy for Early-Stage Cervical Cancer: Comparable Survival Rates but Higher Recurrence Risk

Alcohol and Cancer Risk: Is a Drop Too Much?